Merck's Patent Tactics Violate Antitrust Law: Suit
Merck & Co. Inc. has been hit with a proposed antitrust class action alleging it improperly extended its monopoly on the brain cancer drug Temodar by delaying prosecution of the drug's...To view the full article, register now.
Already a subscriber? Click here to view full article